Table 1.
Characterization of VH-D-JH transcripts obtained from CD138+ cells derived from naive (CD27−) and memory (CD28+) B cells
| Transcript | VH | No. nt mutated/nt sequenced | Mutation frequency, % | No. of replacement/silent mutations |
Total R/S | D | JH | Rearrangement | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FR1 | CDR1 | FR2 | CDR2 | FR3 | ||||||||
| CD27− naive-derived CD138+ plasma cells | ||||||||||||
| R1-1* | VH3-73 | 0/291 | 0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0:0 | D6-13 | JH3 | PR |
| R1-2* | VH3-30.5 | 0/285 | 0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0:0 | D5-5 | JH4 | PR |
| R1-3 | VH3-30 | 34/285 | 11.9 | 1/1 | 3/0 | 0/0 | 9/2 | 12/1 | 25:4 | D6-25 | JH6 | Non-PR |
| R1-5 | VH3-33 | 8/285 | 2.8 | 2/0 | 0/0 | 1/0 | 2/1 | 1/0 | 6:1 | D6-13 | JH4 | PR |
| R1-6 | p1 | 37/285 | 13.0 | 3/2 | 2/0 | 3/0 | 5/3 | 9/2 | 22:7 | D5-24 | JH4 | PR |
| R1-7* | VH3-15 | 0/291 | 0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0:0 | D6-13 | JH6 | PR |
| R1-8 | VH3-53 | 28/282 | 9.9 | 2/1 | 1/0 | 2/0 | 7/1 | 8/2 | 20:4 | D3-3 | JH4 | Non-PR |
| R1-9* | VH3-23 | 1/285 | 0.4 | 0/0 | 0/0 | 0/0 | 0/0 | 1/0 | 1:0 | D6-25 | JH4 | PR |
| R1-11* | VH3-30.5 | 0/285 | 0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0:0 | D5-5 | JH4 | PR |
| R1-12* | VH3-21 | 0/285 | 0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0:0 | D5-5 | JH4 | PR |
| R1-13 | VH3-30.5 | 3/285 | 1.1 | 0/0 | 1/0 | 0/0 | 1/1 | 0/0 | 2:1 | D3-10 | JH4 | PR |
| R1-14* | VH3-15 | 0/291 | 0 | 0/0 | 0/0 | 0/0 | 0/0 | 0/0 | 0:0 | D2-8 | JH6 | PR |
| CD27+ memory-derived CD138+ plasma cells | ||||||||||||
| R2-1 | VH5-51 | 10/285 | 3.5 | 3/1 | 1/0 | 0/0 | 0/0 | 4/1 | 8:2 | D1-7 | JH4 | PR |
| R2-2 | VH3-49 | 13/291 | 4.5 | 2/0 | 1/0 | 0/0 | 4/1 | 3/1 | 10:2 | D3-9 | JH3 | PR |
| R2-4 | VH1-2 | 24/285 | 8.4 | 4/0 | 2/0 | 0/1 | 4/0 | 7/4 | 17:5 | D5-5 | JH4 | PR |
| R2-5 | VH5-51 | 14/285 | 4.9 | 2/2 | 1/0 | 0/0 | 1/1 | 5/1 | 9:4 | D6-13 | JH4 | PR |
| R2-6 | VH3-23 | 16/285 | 5.6 | 2/1 | 2/0 | 0/0 | 5/0 | 1/2 | 10:3 | D2-21 | JH4 | PR |
| R2-7 | VH3-11 | 18/285 | 6.3 | 3/1 | 1/1 | 1/0 | 5/1 | 0/3 | 10:6 | D7-27 | JH6 | PR |
| R2-8 | VH5-51 | 19/285 | 6.7 | 3/1 | 2/0 | 0/1 | 3/1 | 6/0 | 14:3 | — | JH6 | PR |
| R2-9 | VH3-7 | 11/285 | 3.9 | 2/2 | 1/0 | 1/0 | 1/0 | 4/0 | 9:2 | D2-21 | JH4 | Non-PR |
| R2-10 | VH3-64 | 24/285 | 8.4 | 0/1 | 1/1 | 0/0 | 6/1 | 5/2 | 12:5 | — | JH6 | PR |
| R2-11 | VH3-13 | 14/282 | 5.0 | 0/2 | 1/0 | 1/1 | 0/1 | 3/1 | 5:5 | D5-5 | JH6 | PR |
| R2-13 | VH1-2 | 29/285 | 10.2 | 5/1 | 2/0 | 1/0 | 6/1 | 6/3 | 20:5 | D2-8 | JH4 | PR |
| R2-14 | VH3-21 | 14/285 | 4.9 | 0/0 | 2/1 | 0/1 | 3/3 | 0/1 | 5:6 | — | JH6 | PR |
V gene sequence analysis was performed on the CD138+ cells derived from CD27− (naive) and control CD27+ (memory) B cells. Seventy percent of the CD138+ cells derived from CD27− B cells were germ-line configuration without somatic mutations. None of the control, CD138+ cells derived from the CD27+ B cells, were germ-line configuration. nt indicates nucleotide; FR, framework region; CDR, complementarity-determining region; R/S, replacement-to-silent mutation ratio; PR, productive gene rearrangement; and non-PR, nonproductive gene rearrangement.
*
0.99% germ-line identity of the rearranged VH gene.